

GLAXOSMITHKLINE PLC  
Form 6-K  
November 04, 2008

**FORM 6-K**

**SECURITIES AND EXCHANGE COMMISSION  
Washington D.C. 20549**

**Report of Foreign Issuer**

**Pursuant to Rule 13a-16 or 15d-16 of  
the Securities Exchange Act of 1934**

For period ending November 04, 2008

**GlaxoSmithKline plc**  
(Name of registrant)

**980 Great West Road, Brentford, Middlesex, TW8 9GS**  
(Address of principal executive offices)

Indicate by check mark whether the registrant files or  
will file annual reports under cover Form 20-F or Form 40-F

Form 20-F x Form 40-F

--

Indicate by check mark whether the registrant by furnishing the  
information contained in this Form is also thereby furnishing the  
information to the Commission pursuant to Rule 12g3-2(b) under the

Securities Exchange Act of 1934.

Yes No x

--

**Notification of Transactions of Directors, Persons Discharging Managerial Responsibility or Connected Persons**

Following a re-valuation of the cash element of the notional investment held within the US Retirement Savings Plan ("the Plan"), which is notionally held in GSK Ordinary share ADRs, the administrators of the Plan notified GlaxoSmithKline plc and the under-mentioned persons on 3 November 2008 of an increase in the notional allocation of Ordinary share ADRs on 30 October 2008 at a price of \$37.90 per ADR:-

|                    |    |
|--------------------|----|
| Dr M M Slaoui      | 5  |
| Mrs C Bruck Slaoui | 2  |
| Mr E J Gray        | 25 |
| Mr W C Louv        | 12 |
| Dr D Pulman        | 26 |

This  
i  
s notification  
relates to a  
transaction notified in accordance with

Disclosure  
and Transparency Rule 3.1.4R(1)(a  
).

S M Bicknell  
Company Secretary

4 November  
2008

**SIGNATURES**

Edgar Filing: GLAXOSMITHKLINE PLC - Form 6-K

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorised.

**GlaxoSmithKline plc**  
(Registrant)

Date: 04 November, 2008

By: VICTORIA WHYTE

-----

Victoria Whyte  
Authorised Signatory for and on  
behalf of GlaxoSmithKline plc